|
CANDIDIASIS, FAMILIAL, 6
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity.
|
21350122 |
2011 |
|
CANDIDIASIS, FAMILIAL, 6
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity.
|
21350122 |
2011 |
|
CANDIDIASIS, FAMILIAL, 6
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
CANDIDIASIS, FAMILIAL, 6
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Candidiasis, Chronic Mucocutaneous
|
0.450 |
Biomarker
|
disease |
BEFREE |
A recent study showed that autosomal dominant IL17F deficiency could cause chronic mucocutaneous candidiasis.
|
29458167 |
2018 |
|
Candidiasis, Chronic Mucocutaneous
|
0.450 |
Biomarker
|
disease |
BEFREE |
Chronic mucocutaneous candidiasis (CMC) is one of the three major disease components and is, to date, mainly explained by the presence of neutralizing auto-antibodies against cytokines [interleukin (IL)-17A, IL-17F, and IL-22] from T helper 17 cells, which are critical for the protection against fungal infections.
|
28919897 |
2017 |
|
Candidiasis, Chronic Mucocutaneous
|
0.450 |
Biomarker
|
disease |
BEFREE |
Patients with inborn errors of interleukin-17F (IL-17F) or IL-17RA display chronic mucocutaneous candidiasis (CMC).
|
24120361 |
2013 |
|
Candidiasis, Chronic Mucocutaneous
|
0.450 |
GermlineCausalMutation
|
disease |
ORPHANET |
Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity.
|
21350122 |
2011 |
|
Candidiasis, Chronic Mucocutaneous
|
0.450 |
GeneticVariation
|
disease |
BEFREE |
Chronic mucocutaneous candidiasis disease (CMCD) may be caused by autosomal dominant (AD) IL-17F deficiency or autosomal recessive (AR) IL-17RA deficiency.
|
21727188 |
2011 |
|
Candidiasis, Chronic Mucocutaneous
|
0.450 |
Biomarker
|
disease |
BEFREE |
Examples include antigranulocyte macrophage-colony stimulating factor (GM-CSF) autoantibodies and pulmonary alveolar proteinosis; anti-interferon (IFN)-γ autoantibodies and disseminated nontuberculous mycobacteria (NTM); anti-interleukin-(IL)-6 autoantibodies and severe staphylococcal skin infection; anti-IL-17A, anti-IL-17F, or anti-IL-22 autoantibodies in patients with mucocutaneous candidiasis in the setting of both the autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy (APECED) syndrome and in cases of thymoma.
|
20966748 |
2010 |
|
Candidiasis, Chronic Mucocutaneous
|
0.450 |
Biomarker
|
disease |
HPO |
|
|
|
|
Pancreatic carcinoma
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
Genetic polymorphisms associated with pancreatic cancer survival: a genome-wide association study.
|
28470677 |
2017 |
|
Pancreatic carcinoma
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
|
22142827 |
2012 |
|
Pancreatic carcinoma
|
0.110 |
Biomarker
|
disease |
BEFREE |
The variant 161R form of IL-17F is a natural antagonist of the antiangiogenic effects of wild-type 161H IL-17F, and angiogenesis may play an important role in the metastatic spread of pancreatic cancer.
|
22142827 |
2012 |
|
Pancreatic carcinoma
|
0.110 |
GeneticVariation
|
disease |
GWASDB |
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
|
22142827 |
2012 |
|
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We searched three electronic databases (MEDLINE, Scopus and Web of Science) for observational studies assessing the association between susceptibility to RA (or its clinical presentation) and polymorphisms of the cytokines IL-17A, IL-17F, IL-21 and IL-22.
|
31454755 |
2020 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, F. nucleatum orchestrates a molecular network involving CARD3 and IL-17F to control the UC process.
|
31610014 |
2020 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluate the efficacy and safety of dual neutralisation of interleukin (IL)-17A and IL-17F with bimekizumab, a monoclonal IgG1 antibody, in addition to certolizumab pegol (CZP) in patients with rheumatoid arthritis (RA) and inadequate response (IR) to certolizumab pegol.
|
31177099 |
2019 |
|
Asthma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum IgE, IL-17A, IL-17F, and GR-β levels in geriatric patients with moderate or severe asthma were significantly higher than those in young patients with moderate asthma and in the normal population.
|
30304965 |
2019 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Toluene diisocyanate (TDI) is one of the leading allergens of asthma that induces both T-helper Th2 and Th17 responses, and is often associated with poor responsiveness to steroid treatment in the clinic.We sought to evaluate the effects of inhaled and systemic steroids on a TDI-induced asthma model and to find how interleukin (IL)-17A and IL-17F function in this model.
|
30655284 |
2019 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
T helper 17 (Th17) cells, characterized by secretion of IL-17 and IL-17F, are a specialized CD4<sup>+</sup> effector T cell lineage that not only facilitates host defense against pathogen infection and maintenance of mucosal barrier, but also potently induces tissue inflammation and autoimmune diseases.
|
31699215 |
2019 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin-17A (IL-17A) and interleukin-17F (IL-17F) as two potent proinflammatory cytokines and the signature cytokines of Th17 cells play important roles in human autoimmune diseases, inflammation and host defenses.
|
31377676 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-17F effects on cancer cell proliferation, migration, and invasion were studied using a live-imaging IncuCyte system, and a Caspase-3/7 reagent was used for testing apoptosis.
|
31083515 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Th17 T<sub>EM</sub> cells (expressing <i>IL17A, IL17F, RORC</i>, and <i>STAT3</i>) displayed a higher pathogenic/cytotoxic (<i>IL23R, IL18RAP</i>, and <i>GZMB, CD160, PRF1</i>) gene signature in CD relative to UC, while non-pathogenic/regulatory genes (<i>IL9, FOXP3, CTLA4</i>) were more elevated in UC.
|
31191543 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our data indicate that IL-17A rs2275913 polymorphism but not IL-17F rs763780 polymorphism contributes to increased risk for CRC patients in this Chinese population.
|
31682719 |
2019 |